Home › Previous Meetings › BAS Annual meeting 2020 live

BAS Annual meeting 2020 live

BAS Annual Meeting

Thursday 17 – Friday 18 September 2020

Join the BAS livestream for keynote talks, early career investigator competition and rapid fire presentations

As the BAS are unable to host their annual meeting face to face in September we are excited to invite you to join us via a virtual platform for a livestream including keynote presentations, early career investigator competition and rapid fire presentations.

Registration is free to BAS members. Non members wishing to attend should apply for BAS membership.

Programme

BAS Annual Meeting pdf programme
Prof Sir Nilesh SAMANI, and Prof Michael HOLMES

Thursday 17 September 2020

16:00 – 17:00 hours BST
Hugh Sinclair Lecture:
 Biological Ageing and Coronary Artery Disease – a Journey
Prof Sir Nilesh J Samani
 Professor of Cardiology
Department of Cardiovascular Sciences
University of Leicester
Consultant Cardiologist
Medical Director, British Heart Foundation

17:00-18:00 hours BST
Rapid fire presentations

Hugh Sinclair lecture sponsor:

Friday 18 September 2020

10:00 – 12:00 hours BST
Early Career Investigator Competition

11:00 – 12:00 hours BST
John French lecture:
Elucidating the causes of cardiovascular disease through human genetics
Prof Michael Holmes
 Associate Professor and BHF Intermediate Clinical Research Fellow
Medical Research Council Population Health Research Unit,
Nuffield Department of Population Health, University of Oxford

Registration for this meeting closed at 1700 hrs on Wednesday 16 September.  No further registrations from members may be included after this time.

Abstract submission now closed

Authors will be notified of the outcome by early September.

Early Career Investigator Competition sponsored by:

Sponsors

Hugh Sinclair lecture sponsor:
Posted on by AS BAS Posted in Previous Meetings in Previous Meetings

Elucidating the causes of cardiovascular disease through human genetics​

Prof Michael Holmes

Understanding the causes of cardiovascular disease is critical both from an aetiological perspective but also for development of novel efficacious therapies. Observational epidemiology, whilst valuable for hypothesis generation, can be plagued by errors including bias and confounding, limiting the deductions that can be made from such study designs. By contrast, human genetics can provide a tool by which the causal role of an exposure can be more reliably characterized. Performed well, such studies employing a Mendelian randomization approach, can provide rigorous evidence of causation. Indeed, the presence of genetic evidence to support causation increases the probability several-fold of a therapeutic being successful in a phase III cardiovascular outcome trial and obtaining a marketing authorisation.

In this talk, I will describe historical and contemporary applications of Mendelian randomization to elucidating the cardiovascular roles of complex phenotypes and therapeutic targets, and in doing so, showcase the translational utility and opportunities of human genetics as applied to cardiovascular disease.